2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

[1]  R. Wender,et al.  Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2013, Diabetologia.

[2]  S. Inzucchi,et al.  Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379 , 2013, Diabetes Care.

[3]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.

[4]  H. Woerle,et al.  Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme , 2012, Cardiovascular Diabetology.

[5]  Gretchen A. Stevens,et al.  National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants , 2011, The Lancet.

[6]  A. Avogaro,et al.  Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. , 2011, Vascular pharmacology.

[7]  N. Magrini,et al.  Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61 , 2011, Diabetes Care.

[8]  H. Woerle,et al.  Effect of linagliptin monotherapy on glycaemic control and markers of β‐cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial , 2011, Diabetes, obesity & metabolism.

[9]  M. Taskinen,et al.  Safety and efficacy of linagliptin as add‐on therapy to metformin in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled study , 2011, Diabetes, obesity & metabolism.

[10]  V. Basevi.  Standards of Medical Care in Diabetes—2011 , 2011, Diabetes Care.

[11]  J. Eriksson,et al.  Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial , 2010, International journal of clinical practice.

[12]  B. Zinman,et al.  Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study , 2010, Diabetes, obesity & metabolism.

[13]  S. Dejager,et al.  Assessing the cardio–cerebrovascular safety of vildagliptin: meta‐analysis of adjudicated events from a large Phase III type 2 diabetes population , 2010, Diabetes, obesity & metabolism.

[14]  K. Mahaffey,et al.  A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes , 2010, Postgraduate medicine.

[15]  B. Goldstein,et al.  Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes , 2010, BMC endocrine disorders.

[16]  M. Davies,et al.  Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study , 2010, International journal of clinical practice.

[17]  S. Bolge,et al.  Patient-reported tolerability issues with oral antidiabetic agents: Associations with adherence; treatment satisfaction and health-related quality of life. , 2010, Diabetes research and clinical practice.

[18]  P. Elliott,et al.  Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database , 2009, BMJ : British Medical Journal.

[19]  G. Paolisso,et al.  Antidiabetic Oral Treatment in Older People , 2009, Drugs & aging.

[20]  H. Rodbard,et al.  Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. , 2009, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[21]  Grant D. Huang,et al.  Glucose control and vascular complications in veterans with type 2 diabetes. , 2009, The New England journal of medicine.

[22]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[23]  K. Reynolds,et al.  Is the Combination of Sulfonylureas and Metformin Associated With an Increased Risk of Cardiovascular Disease or All-Cause Mortality? , 2008, Diabetes Care.

[24]  Diederick Grobbee,et al.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.

[25]  Michael E. Miller,et al.  Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.

[26]  G. Krishnarajah,et al.  Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: a meta‐analysis , 2008, Diabetes, obesity & metabolism.

[27]  S. Amiel,et al.  Hypoglycaemia in Type 2 diabetes , 2008, Diabetic medicine : a journal of the British Diabetic Association.

[28]  Workgroup on Hypoglycemia.  Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. , 2005, Diabetes care.

[29]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[30]  R. Holman,et al.  Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.

[31]  UK Prospective Diabetes Study Group.  Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration , 2007, Diabetologia.

[32]  Simon Smyth,et al.  Diabetes and obesity: the twin epidemics , 2006, Nature Medicine.